Last reviewed · How we verify

NCT04785677

Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration

Completed NA Results posted Last updated 11 March 2026
What this trial tests

NA trial testing Resiliency in Stressful Experiences (RISE) Program in Stress Disorders, Traumatic in 403 participants. Completed in 30 June 2024.

Timeline
9 February 2021
Primary endpoint
30 May 2023
30 June 2024

Quick facts

Lead sponsorFlorida State University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment403
Start date9 February 2021
Primary completion30 May 2023
Estimated completion30 June 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Florida State University

Who can join

Adults 18 to 35, male only, with Stress Disorders, Traumatic or Stress Disorders, Traumatic, Acute. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Housing Stability Primary · 4 months post release

Stable housing was defined as living in one's own room, apartment, or house, or with family, with an expected duration of residence of 4 months or more, or tenancy rights. A 10- item measure will assess housing stability.

GroupValue95% CI
Treatment Group17
Control Group65
Treatment Group7
Control Group23
Treatment Group172
Control Group119
Housing Stability Primary · 8 months post release

Stable housing was defined as living in one's own room, apartment, or house, or with family, with an expected duration of residence of 4 months or more, or tenancy rights. A 10- item measure will assess housing stability.

GroupValue95% CI
Treatment Group18
Control Group60
Treatment Group8
Control Group29
Treatment Group170
Control Group118
Employment Stability Primary · 4 months post release

Employment Stability is measure on a continuum, based on the number of jobs held in the last 4 months and number of days worked at each Employment. The employment must be for at least 15 hours a week. A 10-item measure will assess employment stability

GroupValue95% CI
Comprehensive Trauma-Based Reentry Program16
Treatment as Usual (TAU)67
Comprehensive Trauma-Based Reentry Program7
Treatment as Usual (TAU)18
Comprehensive Trauma-Based Reentry Program173
Treatment as Usual (TAU)122
Employment Stability Primary · 8 months post release

Employment Stability is based on the number of jobs held in the last 4 months and number of days worked at each Employment. The employment must be for at least 15 hours a week. A 10-item measure will assess employment stability

Employed
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program22
Treatment as Usual (TAU)69
Not Employed
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program4
Treatment as Usual (TAU)18
Non-Responsive
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program170
Treatment as Usual (TAU)120
Brief Symptom Inventory Primary · 4 months post release

Utilizing the Brief Symptom Inventory (BSI) to assess depression and anxiety symptoms in participants. The BSI is a 53-item self-report screening tool that asks respondents to rate their level of psychological distress over the past seven days based on a five-point Likert scale (0 = "not at all" to 5 = "extremely"). The BSI provides subscale scores on dimensions of somatization, depression, and anxiety as well as a Global Severity Index (GSI) that is calculated based on a sum of all items. Subscale scores range from 0 to 4. Higher scores on the BSI indicate higher levels of symptomology.

GroupValue95% CI
Comprehensive Trauma-Based Reentry Program.451± .804
Treatment as Usual (TAU).536± .813
Brief Symptom Inventory Primary · 8 months post release

Utilizing the Brief Symptom Inventory (BSI) to assess depression and anxiety symptoms in participants. The BSI is a 53-item self-report screening tool that asks respondents to rate their level of psychological distress over the past seven days based on a five-point Likert scale (0 = "not at all" to 5 = "extremely"). The BSI provides subscale scores on dimensions of somatization, depression, and anxiety as well as a Global Severity Index (GSI) that is calculated based on a sum of all items. Subscale scores range from 0 to 4. Higher scores on the BSI indicate higher levels of symptomology.

GroupValue95% CI
Comprehensive Trauma-Based Reentry Program.618± .932
Treatment as Usual (TAU).553± .789
Mini International Neuropsychiatric Interview Primary · 4 months post release

Utilizing the 9-item substance use disorder subscale of the MINI International Neuropsychiatric Interview (MINI) to assess current incidence of substance use disorders. Items are rated on a dichotomous Yes/No scale and follow psychiatric guidelines of the DSM-5.

GroupValue95% CI
Comprehensive Trauma-Based Reentry Program8
Treatment as Usual (TAU)22
Comprehensive Trauma-Based Reentry Program21
Treatment as Usual (TAU)67
Depressive Symptoms Secondary · 8 months post release

Depressive symptoms marked by dysphoric mood, inactivity, lack of interest, insomnia, feelings of worthlessness, diminished ability to think, and thoughts of suicide. Depressive symptoms will be measured using the Brief Symptom Inventory, a 53-items with a 6 question sub-scale of depressive symptoms were a respondent characterizes the intensity of distress (0 ="not at all" to 4="extremely").The higher score the more depressive symptoms.

GroupValue95% CI
Comprehensive Trauma-Based Reentry Program.730± .964
Treatment as Usual (TAU).440± .670
Anxiety Symptoms Secondary · 8 months post release

Anxiety symptoms identified as apprehension or fear of impending actual or imagined danger, vulnerability, or uncertainty. Anxiety Symptoms will be measured using the Brief Symptom Inventory is a 53-items with a 6 question sub-scale of anxiety symptoms were a respondent characterizes the intensity of distress (0 ="not at all" to 4="extremely").The higher score the more symptoms of anxiety.

GroupValue95% CI
Comprehensive Trauma-Based Reentry Program.60± 1.15
Treatment as Usual (TAU).574± .812
Incidence of Substance Use Disorder Secondary · 8 months post release

A pathological pattern of impairment related to the overuse of, or dependence on, psychoactive drugs, prescription medications, or other substances. A 9-item substance use disorder subscale of the MINI assesses current incidence of substance use disorders. Items are rated on a dichotomous Yes/No scale and follow psychiatric guidelines of the DSM-5.

Substance Use Disorder
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program9
Treatment as Usual (TAU)23
No Substance Use Disorder
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program20
Treatment as Usual (TAU)67
Coping Self-Efficacy Scale Secondary · 4 months post release

Utilizing the Coping Self-Efficacy Scale (CSES) to assess coping self-efficacy. The CSES is an 26-item self-report tool that asks respondents to indicate if they feel they can do accomplish 26 specific things if when they are having problems. Responses are based on an 11-point Likert scale (0 = "Cannot do at all" to 10 = "Certain can do"). The CSES provides subscale scores on dimensions of problem-focused coping, stopping unpleasant emotions and thoughts, and social support as well as a total coping self-efficacy score that is calculated based on a sum of all items. Problem focused subscale sc

Using Problem-Focused Coping
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program45.58± 8.43
Treatment as Usual (TAU)43.52± 13.45
Stop Unpleasant emotions and thoughts
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program29.1667± 5.75339
Treatment as Usual (TAU)29.4091± 9.03205
Get Support From Friends and Family
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program20.1250± 5.47177
Treatment as Usual (TAU)20.6818± 7.89812
Coping Self-efficacy Secondary · 8 months post release

he CSES is an 26-item self-report tool that asks respondents to indicate if they feel they can do accomplish 26 specific things if when they are having problems. Responses are based on an 11-point Likert scale (0 = "Cannot do at all" to 10 = "Certain can do"). The CSES provides subscale scores on dimensions of problem-focused coping, stopping unpleasant emotions and thoughts, and social support as well as a total coping self-efficacy score that is calculated based on a sum of all items. Problem focused subscale scores range from 0 to 60, emotion-focused subscale scores range from 0 to 40, and

Using Problem-Focused Coping
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program48.23± 10.03
Treatment as Usual (TAU)44.93± 10.16
Stop Unpleasant Emotions and Thoughts
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program30.3462± 8.01470
Treatment as Usual (TAU)29.0449± 8.76967
Get Support From Friends and Family
GroupValue95% CI
Comprehensive Trauma-Based Reentry Program18.3846± 7.46232
Treatment as Usual (TAU)19.8764± 7.20767

Sponsor's own description

The investigators are conducting a randomized controlled trial to assess the impact of Resiliency in Stressful Experiences (RISE) - a comprehensive trauma-based program for young men releasing from a southeastern state's prisons. The investigators are assessing whether treating trauma and providing other transitional supports - such as employment assistance - as young men return home will help to improve their community stability and enhance their psychological well-being, in turn, resulting in less likelihood that a person will become incarcerated in the future.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Study protocol paper for the multisite randomized controlled trial of comprehensive trauma informed reentry services for moderate to high-risk young males releasing from state prisons.
    Pettus C, Renn T, Tripodi S, Tamburri S. · · 2022 · cited 2× · PMID 35470103 · DOI 10.1016/j.cct.2022.106766

Verify or expand the search:

Other recruiting trials for Stress Disorders, Traumatic

Currently open trials in the same condition.

Other Florida State University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04785677.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing